

1 **Preterm birth is associated with immune dysregulation which persists in**  
2 **infants exposed to histologic chorioamnionitis: a descriptive study**

3 Gemma Sullivan<sup>1</sup>, Paola Galdi<sup>1</sup>, Nis Borbye-Lorenzen<sup>2</sup>, David Q. Stoye<sup>1</sup>, Gillian J.  
4 Lamb<sup>1</sup>, Margaret J. Evans<sup>3</sup>, Kristin Skogstrand<sup>2</sup>, Siddharthan Chandran<sup>4,5</sup>, James P.  
5 Boardman<sup>1,4</sup>

6

7 <sup>1</sup> MRC Centre for Reproductive Health, University of Edinburgh, Edinburgh, UK

8 <sup>2</sup> Danish Center for Neonatal Screening, Statens Serum Institut, Copenhagen,  
9 Denmark

10 <sup>3</sup> Department of Pathology, Royal Infirmary of Edinburgh, Edinburgh, UK

11 <sup>4</sup> Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK

12 <sup>5</sup> MRC Centre for Regenerative Medicine, University of Edinburgh, UK

13

14 Running title: Histologic chorioamnionitis and immune dysregulation

15

16 Corresponding author:

17 Dr. Gemma Sullivan

18 MRC Centre for Reproductive Health, Queen's Medical Research Institute, 47 Little

19 France Crescent, Edinburgh, EH16 4TJ, UK.

20 Email: [gemma.sullivan@ed.ac.uk](mailto:gemma.sullivan@ed.ac.uk)

21 Telephone: +44 131 242 2567

22

23

24

25

26 **Abstract**

27 **Objective.** To characterise the umbilical cord blood immune profile in preterm infants

28 compared to term-born controls and the postnatal immune response following

29 exposure to histologic chorioamnionitis (HCA) in preterm infants.

30 **Design.** Descriptive, observational cohort study.

31 **Setting.** Edinburgh, UK.

32 **Population.** 118 preterm infants (mean gestational age 29<sup>+0</sup> weeks, range 23<sup>+2</sup> to

33 32<sup>+0</sup>) and 59 term-born controls.

34 **Methods.** Placental histopathology was used to identify reaction patterns indicative

35 of HCA, and a customised immunoassay of 24 inflammatory markers and trophic

36 proteins selected to reflect the perinatal immune response was performed on

37 umbilical cord blood in term and preterm participants and postnatal day 5 blood in

38 the preterm group.

39 **Results.** The umbilical cord blood immune profile classified gestational age category

40 with 86% accuracy (95% CI 0.78-0.92), p-value=1.242x10<sup>-14</sup>. Pro-inflammatory

41 proteins IL-6, MCP-1 and CRP were elevated in the cord blood of preterm infants

42 whilst BDNF, C3, C9, IL-18, MMP-9 and RANTES were decreased, compared to

43 infants born at term. In preterm infants, exposure to HCA was associated with

44 elevations in 5 immune proteins on postnatal day 5 (BDNF, C3, IL-8, MIP-1 $\beta$  and

45 MMP-9) when compared to preterm infants who were not exposed.

46 **Conclusion.** Preterm birth is associated with a distinct immune profile in umbilical

47 cord blood and infants exposed to HCA experience specific alterations in immune

48 function that persist to day 5 of postnatal life.

49

50 **Keywords.** brain derived neurotrophic factor, complement, cytokine, fetal  
51 inflammatory response, human, inflammation, innate immunity, interleukin, preterm  
52 birth  
53

## 54 **Introduction**

55 Perinatal immune processes have a crucial role in neurodevelopment and early life  
56 inflammatory exposures are associated with an increased risk of neuropsychiatric  
57 disorders such as autism spectrum disorder, schizophrenia, bipolar disorder and  
58 depression<sup>1,2</sup>. Preterm infants may be exposed to multiple episodes of perinatal  
59 infection/inflammation and are particularly vulnerable to brain injury resulting from a  
60 dysregulated immune response during a critical period of CNS development<sup>3</sup>.

61

62 Preterm infants have a distinct immune profile in umbilical cord blood and  
63 cerebrospinal fluid that includes higher levels of pro-inflammatory cytokines and  
64 lower levels of growth factors when compared to term-born controls but there is  
65 uncertainty about the extent to which this is influenced by antenatal factors,  
66 environmental exposures and/or developmental regulation<sup>4,5,6</sup>. Histologic  
67 chorioamnionitis (HCA) is strongly associated with preterm birth<sup>7,8</sup> and increases  
68 the risk of neonatal morbidities including lung disease, intraventricular haemorrhage,  
69 sepsis and necrotising enterocolitis<sup>9-14</sup>. HCA has also been implicated in the  
70 development of white matter injury, cerebral palsy and neurodevelopmental  
71 impairment<sup>15-18</sup> and this may be mediated by specific pro-inflammatory cytokines<sup>19</sup>.  
72 When HCA involves a fetal inflammatory response (FIR), these risks appear to be  
73 increased further, suggesting that organ injury is mediated by a systemic fetal  
74 inflammatory response syndrome (FIRS). FIRS was initially defined using threshold  
75 values of IL-6 concentration in umbilical cord blood<sup>20,21</sup> although subsequent  
76 studies have shown that histopathological FIR is associated with elevated  
77 concentrations of cytokines (IL-1 $\beta$ , IL-6 and TNF- $\alpha$ ), chemokines (IL-8, MCP-1, MIP-  
78 1 $\beta$ , RANTES), matrix metalloproteinases (MMP-1 and MMP-9) and CRP<sup>19,22-26</sup>. In

79 some preterm infants, blood concentrations of inflammatory mediators remain  
80 elevated for weeks after birth<sup>27,28</sup> and may be associated with higher circulating  
81 levels of neurotrophic growth factors<sup>29</sup>. However, neurotrophic capability following  
82 exposure to intrauterine inflammation is not well understood and previous study  
83 designs leave uncertainty about the role of the complement system in perinatal  
84 inflammation, which plays a critical role in the innate immune response.

85

86 Preterm infants could benefit from immunomodulatory therapies in the perinatal  
87 period but development of rational treatment strategies requires improved  
88 characterisation of the neonatal immune profile and the postnatal response to HCA.  
89 In this study, an immunoassay of 24 analytes customised to reflect the perinatal  
90 immune response was used to analyse profiles from umbilical cord and postnatal  
91 blood with placental histopathology to (1) characterise the intrauterine immune  
92 environment of preterm infants compared to term-born controls, and (2) test the  
93 hypothesis that exposure to histologic chorioamnionitis is associated with an altered  
94 immune and neurotrophic profile in the first week after very preterm birth.

95

## 96 **Materials and Methods**

### 97 **Study population**

98 Participants were 177 infants, 118 very preterm (mean gestational age 29<sup>+0</sup> weeks,  
99 range 23<sup>+2</sup> to 32<sup>+0</sup>) and 59 term-born controls, delivered at the Royal Infirmary of  
100 Edinburgh, UK and recruited to a longitudinal study of the effect of preterm birth on  
101 brain development<sup>30</sup>. Ethical approval was obtained from the UK National Research  
102 Ethics Service and parents provided written informed consent (South East Scotland  
103 Research Ethics Committee 16/SS/0154). Subsets were used to characterise the

104 umbilical cord blood immune profile of preterm infants when compared to term-born  
105 controls (n=114), and the immune profile on postnatal day 5 in preterm infants who  
106 were exposed to HCA compared to those not exposed (n=96).

107

#### 108 **Dried blood spot sample analysis**

109 Dried blood spot samples (DBSS) were taken from the umbilical cord following  
110 delivery for both preterm cases and term-born controls. For preterm infants, an  
111 additional sample was collected on day 5 of life. A customised multiple sandwich  
112 immunoassay based on meso-scale technology was used to measure blood spot  
113 levels of Interleukin(IL)1- $\beta$ , IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12p70, IL-17, IL-18,  
114 Monocyte chemotactic protein-1 (MCP-1), Macrophage inflammatory protein-1 $\alpha$   
115 (MIP-1 $\alpha$ ), Macrophage inflammatory protein-1 $\beta$  (MIP-1 $\beta$ ), Tumor necrosis factor- $\alpha$   
116 (TNF- $\alpha$ ), Tumor necrosis factor- $\beta$  (TNF- $\beta$ ), Brain-derived neurotropic factor (BDNF),  
117 Granulocyte-macrophage colony-stimulating factor (GM-CSF), Interferon- $\gamma$  (IFN- $\gamma$ ),  
118 C-reactive protein (CRP), matrix-metalloproteinase 9 (MMP-9), Regulated upon  
119 activation, normal T cell expressed and secreted (RANTES) and Complement  
120 components C3, C5a and C9.

121

122 Two 3.2 mm disks from the DBSS were punched into each well of Nunc 96-well  
123 polystyrene microwell plates (#277143, Thermo Fisher Scientific). 130  $\mu$ l extraction  
124 buffer (PBS containing 1% BSA (Sigma Aldrich #A4503), 0.5% Tween-20  
125 (#8.22184.0500, Merck Millipore), and complete protease inhibitor cocktail  
126 (#11836145001, Roche Diagnostics) was added to each well, and the samples were  
127 incubated for 1 hour at room temperature on a microwell shaker set at 900 rpm. The  
128 extracts were analysed using U-plex plates (Meso-Scale Diagnostics (MSD),

129 Maryland, US) coated with antibodies specific for IL-1 $\beta$ , IL-2, IL-4, IL-5, IL-6, IL-8, IL-  
130 12, IL-17, TNF- $\alpha$ , MIP-1 $\beta$  on one plate (#K15067 customized) and BDNF, GM-CSF,  
131 IL-10, IL-18, IFN- $\gamma$ , TNF- $\beta$ , MCP-1, MIP-1 $\alpha$  on another (#K151AC customized) (both  
132 MSD). Supplier's instructions were followed, and extracts were analysed undiluted.  
133 A third multiplex analysis was developed in-house applying extracts diluted 1:10 in  
134 diluent 7 (#R54BB, MSD) using antibodies specific for C3 (HYB030-07 and HYB030-  
135 06, SSI Antibodies, Copenhagen, Denmark), C5a (10604-MM04 and 10604-MM06,  
136 Sino Biological, Eschborn, Germany), C9 (R-plex kit #F21XZ, MSD), MMP-9  
137 (BAF911 and MAB911), RANTES (MAB278 and AF278NA) and CRP (BAM17072  
138 and MAB1701) (all R&D Systems, Minneapolis, US) for coating the U-plex plate and  
139 for detection, respectively. Coating antibodies (used at 1  $\mu$ g/mL, except CRP used at  
140 10 ng/mL) were biotinylated (using EZ-Link Sulfo-NHS-LC-Biotin #21327, Thermo  
141 Fisher Scientific) in-house (if not already biotinylated at purchase) and detection  
142 antibodies were SULFO-tagged (R91AO, MSD), both at a challenge ratio of 20:1.  
143 The following calibrators were used: C3: #PSP-109 (Nordic Biosite, Copenhagen,  
144 DK), C5a: #10604-HNAE (Sino Biological), C9: #F21XZ (from R-plex kit, MSD),  
145 MMP-9: #911-MP, RANTES: #278-RN and CRP: #1707-CR/CF (all from R&D  
146 Systems). Calibrators were diluted in diluent 7, detection antibodies (used at 1  
147  $\mu$ g/mL, except CRP used at 100 ng/mL) were diluted in diluent 3 (#R50AP, MSD).  
148 Controls were made in-house from part of the calibrator solution in one batch,  
149 aliquoted in portions for each plate and stored at -20°C until use. The samples were  
150 prepared on the plates as recommended from the manufacturer and were  
151 immediately read on the QuickPlex SQ 120 (MSD). Analyte concentrations were  
152 calculated from the calibrator curves on each plate using 4PL logistic regression  
153 using the MSD Workbench software. Intra-assay variations were calculated from 16

154 measurements of a pool of the same control sample on the same plate. Inter-assay  
155 variations were calculated from controls analysed in duplicate on each plate during  
156 the sample analysis, 4 plates in total. Limits of detection were calculated as 2.5  
157 standard deviations from duplicate measurements of the zero calibrator. The higher  
158 detection limit was defined as the highest calibrator concentration. Median intra-  
159 assay variation was 8.2% and median inter-assay variation was 11.1%. Detection  
160 limits are detailed in Table S1.

161

### 162 **Placental examination**

163 Placental examination was performed by an experienced perinatal pathologist  
164 (M.J.E.) and placental reaction patterns were reported according to the site of  
165 inflammation, using a structured system<sup>31</sup>. HCA was defined as the presence of an  
166 inflammatory response in the placental membranes of any grade or stage. Maternal  
167 inflammatory response (MIR) was defined as the presence of chorionitis,  
168 chorioamnionitis or intervillitis. Fetal inflammatory response (FIR) was defined as  
169 the presence of vasculitis in the chorionic plate or funisitis involving any vessel of the  
170 umbilical cord.

171

### 172 **Statistical analysis**

173 Participant characteristics were compared using Student's T test or Mann-Whitney U  
174 to compare distributions, and Chi-square tests were used to compare proportions.  
175 Analytes with values less than the level of detection (<LOD) were assigned the  
176 lowest detectable level prior to statistical analysis, and analytes with concentrations  
177 <LOD in  $\geq 75\%$  of samples were excluded from subsequent statistical analysis.

178 To investigate group differences in blood immune mediator profiles, the Mann-  
179 Whitney U was used with Bonferroni correction for multiple tests. Principal  
180 component analysis (PCA) was used to identify analytes contributing to variance in  
181 the cord blood profile and analytes that contributed to PCs with eigenvalues >1 were  
182 then entered as independent variables in a logistic regression model to predict  
183 preterm or term category. Analytes contributing to variability within PCs predictive of  
184 gestational category were then investigated individually using Spearman's rank order  
185 correlation to identify developmentally regulated analytes most strongly correlated  
186 with gestational age.

187 For mediators differentially expressed on day 5, exploratory analyses were  
188 performed to characterise the trajectory of immune mediators from birth to postnatal  
189 day 5 in association with HCA. Statistical analyses were performed using SPSS  
190 version 24.0 (IBM Corp., Armonk, NY), with the exception of PCA, which was  
191 performed using R version 3.6.1 (R Core Team, 2019).

192

## 193 **Results**

### 194 **Participants**

195 The clinical characteristics of participants are shown in Table 1.

196

197

198

199

200

201

202

203 **Table 1. Clinical characteristics of participants.**

204

	<b>Preterm n= 118</b>	<b>Term n= 59</b>
Mean gestational age, weeks (range)	29 <sup>+0</sup> (23 <sup>+2</sup> to 32 <sup>+0</sup> )	39 <sup>+4</sup> (37 <sup>+3</sup> to 42 <sup>+0</sup> )
Birthweight, g (SD)	1213 (408)	3549 (515)
Male sex, n (%)	67 (57)	30 (51)
Maternal demographics		
BMI, mean (SD)	27.7 (7.3)	26.4 (5.5)
Current smoker, n (%)	18 (15)	1 (2)
SIMD2016 quintile, n (%)		
1	23 (20)	5 (8)
2	22 (19)	6 (10)
3	26 (22)	11 (19)
4	20 (17)	17 (29)
5	23 (20)	20 (34)
Not known	4	
Pregnancy complications, n (%)		
Pre-eclampsia	13 (11)	3 (5)
Prolonged rupture of membranes	27 (23)	0 (0)
Delivery mode, n (%):		
Vaginal	48 (41)	23 (39)
Emergency caesarean	70 (59)	10 (17)
-Pre-labour	48 (69)	1 (10)
-In labour	22 (31)	9 (90)
Elective caesarean	0 (0)	26 (44)
Any labour, n (%)	70 (59)	32 (54)
Histologic chorioamnionitis, n (%)	41 (35)	10 (17)
MIR+ FIR-	18 (44)	2 (20)
MIR+ FIR+	23 (56)	8 (80)
Antenatal steroids (%)	112 (95)	NA
Antenatal magnesium sulphate (%)	108 (92)	NA
Early onset sepsis (%)	9 (8)	0
Late onset sepsis (%)	14 (12)	0
Bronchopulmonary dysplasia (%)	32 (27)	NA
Necrotizing enterocolitis (%)	8 (7)	NA
Retinopathy of prematurity (%)	8 (7)	NA
Deaths before discharge (%)	10 (9)	NA

205 SIMD2016: Scottish Index of Multiple Deprivation 2016. Prolonged rupture of membranes for >24  
 206 hours before delivery. Sepsis: Positive blood culture with a pathogenic organism and/or antibiotic  
 207 treatment course for ≥5 days. Early-onset sepsis: <72 hours after birth, late-onset sepsis: >72  
 208 hours after birth. Bronchopulmonary dysplasia: supplemental oxygen therapy or respiratory  
 209 support at 36<sup>+0</sup> weeks gestational age. Necrotizing enterocolitis: medical treatment for ≥7 days or  
 210 surgical treatment. Retinopathy of prematurity requiring treatment with laser therapy. Prolonged  
 211 rupture of membranes >24 hours.

212 **Umbilical cord blood profile associated with preterm birth**

213 DBSS were obtained from the umbilical cord of 55 preterm infants and 59 term-born  
214 controls. 10 analytes (GM-CSF, IFN- $\gamma$ , IL-2, IL-4, IL-5, IL-10, IL-12, IL-17, MIP-1 $\alpha$   
215 and TNF- $\beta$ ) were <LOD in  $\geq 75\%$  of samples and were therefore excluded from  
216 subsequent analysis. Median and interquartile range of analytes are shown in Table  
217 2.


218 **Table 2. Cord blood analytes in preterm infants and term-born controls.**

Analyte (pg/ml)	Preterm n=55		Term n=59		p-value
	Median	Q1, Q3	Median	Q1, Q3	
BDNF	22.27	6.04, 36.90	62.33	43.18, 113.68	<0.001
C3	3081995.73	1858060.85, 4569905.86	4447458.83	3520957.75, 5613382.51	<0.001
C5a	3694.52	2420.56, 11470.85	7136.48	4059.83, 9443.64	0.028
C9	1236.73	215.00, 6901.99	12628.69	3608.60, 43156.07	<0.001
CRP	100.88	89.00, 12054.79	89.00	89.00, 89.00	<0.001
IL-1 $\beta$	0.26	0.26, 0.49	0.11	0.02, 0.34	0.009
IL-6	0.45	0.45, 6.00	0.45	0.45, 0.45	<0.001
IL-8	12.05	5.75, 81.08	8.29	4.89, 14.71	0.049
IL-18	25.62	10.35, 38.34	41.27	27.50, 54.78	<0.001
MCP-1	109.09	68.69, 210.75	48.12	38.54, 66.63	<0.001
MIP-1 $\beta$	12.01	7.47, 18.82	9.72	6.88, 18.24	0.397
MMP-9	14000.68	4485.50, 40077.02	155885.89	87194.67, 358084.73	<0.001
RANTES	1460.12	702.74, 2754.37	3127.55	1817.10, 5295.39	<0.001
TNF- $\alpha$	0.27	0.27, 0.37	0.27	0.27, 0.27	0.521

219

220

221 There were significant group differences for 9 immune mediators ( $p < 0.004$ ,  
222 Bonferroni corrected). Pro-inflammatory proteins IL-6, MCP-1 and CRP were  
223 elevated in the cord blood of preterm infants whilst BDNF, C3, C9, IL-18, MMP-9 and  
224 RANTES were decreased compared to controls born at term. PCA showed that five  
225 principal components (eigenvalues  $> 1$ ) explained 76% of the variance in the cord  
226 blood profile with the majority of variance explained by the first two components  
227 (25% and 20% respectively, Table S2). Projection of individual inflammatory profiles  
228 onto the first two principal components is shown in Figure 1.  
229



230  
231  
232 Figure 1. Projection of individual cord blood inflammatory profiles onto the first two  
233 principal components, grouped by gestational age category.  
234

235 In a logistic regression model to predict preterm or term category based on cord  
236 blood profile, principal components predicted gestational age category with a  
237 classification accuracy of 86% (95% CI 0.78-0.92),  $p$  value =  $1.242 \times 10^{-14}$  (Table S3).  
238 The percentage contribution of each analyte to the principal components is shown in  
239 Figure S1. Amongst immune mediators contributing to variability within the principal  
240 components that predicted gestational category, correlation analysis showed that

241 cord blood MMP-9 and BDNF were highly correlated with gestational age at birth  
242 ( $\rho > 0.65$ ,  $p < 0.001$ ) (Table S4).


243

244 **Histologic chorioamnionitis is associated with an altered immune profile on**  
245 **day 5 after very preterm birth**

246 Of 96 preterm infants with day 5 samples, 31 (32%) were exposed to HCA. Infants  
247 with HCA exposure had lower GA at birth than infants without HCA: mean GA  $28^{+2}$   
248 weeks versus  $29^{+4}$  weeks ( $p = 0.004$ ). Infants exposed to HCA were more likely to  
249 have been delivered vaginally ( $p < 0.001$ ) and more likely to have prolonged rupture  
250 of membranes prior to delivery ( $p < 0.001$ ). There were no statistically significant  
251 group differences in birthweight, infant sex, exposure to antenatal corticosteroids or  
252 magnesium sulphate for fetal neuroprotection, or early onset sepsis (Table S5).

253

254 5 immune proteins on day 5 of life had a median level in preterm infants exposed to  
255 HCA outside the IQR for preterm infants who were not exposed: BDNF, C3a, IL-8,  
256 MIP-1 $\beta$  and MMP-9 (Table S6). In exploratory analyses we considered the trajectory  
257 of analytes over time in a subset of 33 preterm infants who had blood obtained from  
258 the umbilical cord at delivery and on postnatal day 5. Fourteen infants (42%) were  
259 exposed to HCA and eight of those (57%) had evidence of FIR. The 5 mediators that  
260 were elevated on day 5 in association with HCA showed markedly different  
261 trajectories from birth, and this was influenced by placental histological evidence of a  
262 fetal inflammatory response (Figure 2).



263  
264 Figure 2. Analyte trajectories from umbilical cord to postnatal day 5 in preterm infants  
265 exposed to histologic chorioamnionitis compared to those not exposed.

266  
267 BDNF and C3 were elevated at both time points in infants with evidence of placental  
268 FIR. The differences in cord blood concentrations of IL-8 and MIP-1 $\beta$  in infants with  
269 FIR compared to those without were less discriminatory by day 5 whilst altered  
270 MMP-9 expression emerged in the postnatal period.

271

## 272 Discussion

### 273 Main findings

274 By combining placental histopathology with a customised array of immune mediators  
275 in umbilical cord blood and postnatal blood from a large group of mother-infant  
276 dyads, this study characterises differences in the systemic immune profile of very  
277 preterm infants compared with term-born controls, and demonstrates that exposure  
278 to HCA with evidence of a fetal inflammatory response is associated with postnatal  
279 immune dysregulation on day 5 after birth.

280

281 The umbilical cord blood immune profile was distinctly pro-inflammatory in preterm  
282 infants with significant elevations in proteins associated with the acute phase  
283 response: IL-6, MCP-1 and CRP. In contrast, six proteins were elevated in healthy  
284 term-born controls, suggesting developmental regulation with increasing gestational  
285 age: BDNF, C3, C9, IL-18, MMP-9 and RANTES. Five proteins were increased on  
286 postnatal day 5 in preterm infants exposed to HCA compared to preterm infants  
287 without HCA: BDNF, C3, IL-8, MIP-1 $\beta$  and MMP-9. Our findings are consistent with  
288 previous studies showing that the neonatal systemic inflammatory response can be  
289 dysregulated and prolonged in the weeks after preterm birth <sup>4, 27, 28, 32</sup>, but  
290 additionally suggest that this is programmed by a fetal inflammatory response.

291

### 292 **Strengths and limitations**

293 We investigated a large number of inflammation-associated proteins representative  
294 of the perinatal immune response in the newborn, and used a data driven approach  
295 to characterise the inflammatory profile associated with very preterm birth and  
296 exposure to HCA.

297 A limitation of the study is that the concentration of anti-inflammatory cytokines IL-4  
298 and IL-10 were below the level of detection in our participants and so inferences  
299 about the balance of damaging and protective factors could not be explored. Another  
300 limitation is that amniotic fluid was not available for microbial analysis. Recent  
301 transcriptomic studies have shown that the presence of a fetal inflammatory  
302 response is more strongly associated with microbial invasion rather than sterile  
303 inflammation<sup>33</sup> but an alternative study design would be required to investigate

304 differences in the postnatal immune profile of infants exposed to intra-amniotic  
305 infection compared to sterile inflammation.

306 Whilst we found an altered trajectory of immune mediators in association with a fetal  
307 inflammatory response on postnatal day 5, a larger sample size would be required to  
308 perform sub-group analyses based on gestational age or sex and to investigate  
309 possible confounding by postnatal events.

310

### 311 **Interpretation**

312 BDNF expression has previously been shown to correlate with gestational age and  
313 postnatal age<sup>29, 34</sup> but here we show upregulation in preterm infants exposed to  
314 HCA. BDNF belongs to the family of neurotrophins: an important group of signaling  
315 molecules responsible for neuronal growth, maturation and synaptic plasticity during  
316 development<sup>35</sup>. Prematurity, placental dysfunction and fetal growth restriction have  
317 all been associated with reduced levels of BDNF<sup>29, 36-38</sup> which may have important  
318 implications for long-term brain health. Reduced BDNF in the neonatal period has  
319 been associated with increased risk of developing ASD<sup>39</sup> whilst elevated BDNF in  
320 the weeks after preterm birth is associated with better cognitive performance in  
321 childhood<sup>40, 41</sup>.

322

323 C3 was identified as a novel postnatal marker of exposure to intrauterine  
324 inflammation. The complement cascade plays a key role in the innate immune  
325 response<sup>42</sup> but is a potent inflammatory system which when dysregulated can cause  
326 significant tissue damage following injury. The complement cascade can be  
327 activated through several mechanisms, but all component pathways converge at  
328 Complement protein C3<sup>43</sup>. C3 participates in multiple key processes affecting

329 developing brain architecture, including tagging of synapses for pruning by microglia  
330 <sup>44, 45</sup>. The complement system is under-developed in preterm infants and  
331 complement regulators are low <sup>46, 47</sup>, which may contribute to an uncontrolled  
332 complement response in the context of inflammation <sup>48</sup>. We have previously shown  
333 that the downstream anaphylatoxin, C5a is elevated in the CSF of preterm infants  
334 when compared to term-born controls <sup>6</sup> and numerous studies beyond the neonatal  
335 period have also implicated complement C3 dysregulation in CNS pathology  
336 including neurodevelopmental disorders <sup>49</sup>, multiple sclerosis <sup>50</sup>, traumatic brain  
337 injury <sup>51</sup> and neurodegeneration <sup>52</sup>.

338

339 MMP-9 on postnatal day 7 has previously been shown to correlate with the severity  
340 of funisitis following extremely preterm birth<sup>27</sup>. MMP-9 is a member of the zinc-  
341 dependent endopeptidases that prototypically cleave extracellular matrix (ECM), cell  
342 adhesion molecules and cell surface receptors. Matrix-metalloproteinases also  
343 modulate the inflammatory response through the regulation of endothelial barrier  
344 function, cytokine activity and chemotactic gradient formation <sup>53</sup>.

345 The ECM is a key regulator of neural network development and plasticity through the  
346 stabilization of synaptic contacts. Dysregulation of MMP-9 during a critical window of  
347 CNS vulnerability may therefore have long-term consequences on structural  
348 connectivity <sup>54</sup>. MMP-9 is higher in the CSF of preterm infants when compared to  
349 term-born controls and also higher amongst preterm infants with post haemorrhagic  
350 ventricular dilatation (PHVD) when compared to those without brain injury <sup>6,55</sup>.

351 Elevated plasma MMP-9 is also associated with hypoxic-ischemic encephalopathy,  
352 correlating with severity of injury in human infants born at term <sup>56-58</sup>.

353

354 Our data suggest that systemic fetal inflammation modulates neurotrophic capability  
355 and complement system activation in the perinatal period. Future work is needed to  
356 explore whether this altered immune profile extends beyond the first weeks of life  
357 and to investigate the relationship between these immune mediators and lung  
358 disease, gastrointestinal complications and neurodevelopmental outcomes following  
359 preterm birth.

360

### 361 **Conclusions**

362 By combining placental histopathology with a comprehensive assessment of immune  
363 mediators, we have shown that very preterm infants have a distinct pro-inflammatory  
364 profile in umbilical cord blood and the immune profile of infants exposed to HCA  
365 remains altered on day 5 after birth. These results focus research attention on  
366 improved detection of fetuses exposed to intrauterine inflammation and they suggest  
367 there may be a therapeutic window for targeted intervention that could reduce the  
368 risk of co-morbidities associated with HCA.

369

### 370 **Acknowledgements**

371 We are grateful to the families who consented to participate in the study.

372

### 373 **Disclosure of interests**

374 The authors report no financial disclosures or conflicts of interest.

375

### 376 **Contribution to authorship**

377 G.S. conceived and designed the study, acquired and analysed data, and drafted the  
378 article.

379 P.G., M.J.E. analysed data and revised the article critically for important intellectual  
380 content.

381 N.B-L., K.S. acquired data, analysed data and revised the article critically for  
382 important intellectual content.

383 D.Q.S., G.J.L. acquired data, and revised the article critically for important  
384 intellectual content.

385 S.C. supervised acquisition of data and revised the article critically for important  
386 intellectual content.

387 J.P.B. conceived and designed the study, supervised acquisition of data, analysed  
388 data and drafted the article.

389 All authors approved the final submitted version.

390

### 391 **Details of ethics approval**

392 Ethical approval was obtained from the UK National Research Ethics Service (South  
393 East Scotland Research Ethics Committee 16/SS/0154).

394

### 395 **Funding**

396 Financial support for this study was provided by Theirworld ([www.theirworld.org](http://www.theirworld.org)).

397 This work was undertaken in the Medical Research Council Centre for Reproductive  
398 Health, which is funded by a Medical Research Council Centre grant (Medical  
399 Research Council G1002033).

400

401

402

403

## 404 References

- 405 1. Al-Haddad BJS, Oler E, Armistead B, Elsayed NA, Weinberger DR, Bernier R,  
406 et al. The fetal origins of mental illness. *American journal of obstetrics and*  
407 *gynecology*. 2019 Dec;221(6):549-62.
- 408 2. Pape K, Tamouza R, Leboyer M, Zipp F. Immunoneuropsychiatry - novel  
409 perspectives on brain disorders. *Nature reviews Neurology*. 2019 Jun;15(6):317-28.
- 410 3. Hagberg H, Mallard C, Ferriero DM, Vannucci SJ, Levison SW, Vexler ZS, et  
411 al. The role of inflammation in perinatal brain injury. *Nature reviews Neurology*. 2015  
412 Apr;11(4):192-208.
- 413 4. Skogstrand K, Hougaard DM, Schendel DE, Bent NP, Svaerke C, Thorsen P.  
414 Association of preterm birth with sustained postnatal inflammatory response.  
415 *Obstetrics and gynecology*. 2008 May;111(5):1118-28.
- 416 5. Matoba N, Yu Y, Mestan K, Pearson C, Ortiz K, Porta N, et al. Differential  
417 patterns of 27 cord blood immune biomarkers across gestational age. *Pediatrics*.  
418 2009 May;123(5):1320-8.
- 419 6. Boardman JP, Ireland G, Sullivan G, Pataky R, Fleiss B, Gressens P, et al.  
420 The Cerebrospinal Fluid Inflammatory Response to Preterm Birth. *Frontiers in*  
421 *physiology*. 2018;9:1299.
- 422 7. Romero R, Gómez R, Chaiworapongsa T, Conoscenti G, Kim JC, Kim YM.  
423 The role of infection in preterm labour and delivery. *Paediatric and perinatal*  
424 *epidemiology*. 2001 Jul;15 Suppl 2:41-56.
- 425 8. Goldenberg RL, Hauth JC, Andrews WW. Intrauterine infection and preterm  
426 delivery. *The New England journal of medicine*. 2000 May 18;342(20):1500-7.
- 427 9. Bose C, Laughon M, Allred EN, Van Marter LJ, O'Shea TM, Ehrenkranz RA,  
428 et al. Blood protein concentrations in the first two postnatal weeks that predict  
429 bronchopulmonary dysplasia among infants born before the 28th week of gestation.  
430 *Pediatric research*. 2011 Apr;69(4):347-53.
- 431 10. Villamor-Martinez E, Álvarez-Fuente M, Ghazi AMT, Degraeuwe P,  
432 Zimmermann LJI, Kramer BW, et al. Association of Chorioamnionitis With  
433 Bronchopulmonary Dysplasia Among Preterm Infants: A Systematic Review, Meta-  
434 analysis, and Metaregression. *JAMA network open*. 2019 Nov 1;2(11):e1914611.
- 435 11. Been JV, Lieveense S, Zimmermann LJ, Kramer BW, Wolfs TG.  
436 Chorioamnionitis as a risk factor for necrotizing enterocolitis: a systematic review  
437 and meta-analysis. *The Journal of pediatrics*. 2013 Feb;162(2):236-42.e2.
- 438 12. Hofer N, Kothari R, Morris N, Müller W, Resch B. The fetal inflammatory  
439 response syndrome is a risk factor for morbidity in preterm neonates. *American*  
440 *journal of obstetrics and gynecology*. 2013 Dec;209(6):542.e1-.e11.
- 441 13. Ozalkaya E, Karatekin G, Topcuoğlu S, Gürsoy T, Ovalı F. Morbidity in  
442 preterm infants with fetal inflammatory response syndrome. *Pediatrics international :  
443 official journal of the Japan Pediatric Society*. 2016 Sep;58(9):850-4.
- 444 14. Francis F, Bhat V, Mondal N, Adhisivam B, Jacob S, Dorairajan G, et al. Fetal  
445 inflammatory response syndrome (FIRS) and outcome of preterm neonates - a  
446 prospective analytical study. *The journal of maternal-fetal & neonatal medicine : the  
447 official journal of the European Association of Perinatal Medicine, the Federation of  
448 Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstet.*  
449 2019 Feb;32(3):488-92.
- 450 15. Venkatesh KK, Leviton A, Hecht JL, Joseph RM, Douglass LM, Frazier JA, et  
451 al. Histologic chorioamnionitis and risk of neurodevelopmental impairment at age 10

- 452 years among extremely preterm infants born before 28 weeks of gestation. *American*  
453 *journal of obstetrics and gynecology*. 2020 2020/05/07/.
- 454 16. Shatrov JG, Birch SC, Lam LT, Quinlivan JA, McIntyre S, Mendz GL.  
455 Chorioamnionitis and cerebral palsy: a meta-analysis. *Obstetrics and gynecology*.  
456 2010 Aug;116(2 Pt 1):387-92.
- 457 17. Leviton A, Allred EN, Kuban KC, Hecht JL, Onderdonk AB, O'Shea T M, et al.  
458 Microbiologic and histologic characteristics of the extremely preterm infant's placenta  
459 predict white matter damage and later cerebral palsy. the ELGAN study. *Pediatric*  
460 *research*. 2010 Jan;67(1):95-101.
- 461 18. Anblagan D, Pataky R, Evans MJ, Telford EJ, Serag A, Sparrow S, et al.  
462 Association between preterm brain injury and exposure to chorioamnionitis during  
463 fetal life. *Scientific reports*. 2016 Dec 1;6:37932.
- 464 19. Sullivan G, Galdi P, Cabez MB, Borbye-Lorenzen N, Stoye DQ, Lamb GJ, et  
465 al. Interleukin-8 dysregulation is implicated in brain dysmaturation following preterm  
466 birth. *Brain, behavior, and immunity*. 2020 2020/11/01/;90:311-8.
- 467 20. Gomez R, Romero R, Ghezzi F, Yoon BH, Mazor M, Berry SM. The fetal  
468 inflammatory response syndrome. *American journal of obstetrics and gynecology*.  
469 1998 Jul;179(1):194-202.
- 470 21. Gotsch F, Romero R, Kusanovic JP, Mazaki-Tovi S, Pineles BL, Erez O, et al.  
471 The fetal inflammatory response syndrome. *Clinical obstetrics and gynecology*. 2007  
472 Sep;50(3):652-83.
- 473 22. Hecht JL, Fichorova RN, Tang VF, Allred EN, McElrath TF, Leviton A.  
474 Relationship Between Neonatal Blood Protein Concentrations and Placenta  
475 Histologic Characteristics in Extremely Low GA Newborns. *Pediatric research*. 2011  
476 Jan;69(1):68-73.
- 477 23. Døllner H, Vatten L, Halgunset J, Rahimipoor S, Austgulen R. Histologic  
478 chorioamnionitis and umbilical serum levels of pro-inflammatory cytokines and  
479 cytokine inhibitors. *BJOG : an international journal of obstetrics and gynaecology*.  
480 2002 May;109(5):534-9.
- 481 24. Mestan K, Yu Y, Thorsen P, Skogstrand K, Matoba N, Liu X, et al. Cord blood  
482 biomarkers of the fetal inflammatory response. *The journal of maternal-fetal &*  
483 *neonatal medicine : the official journal of the European Association of Perinatal*  
484 *Medicine, the Federation of Asia and Oceania Perinatal Societies, the International*  
485 *Society of Perinatal Obstet*. 2009 May;22(5):379-87.
- 486 25. Armstrong-Wells J, Donnelly M, Post MD, Manco-Johnson MJ, Winn VD,  
487 Sebire G. Inflammatory predictors of neurologic disability after preterm premature  
488 rupture of membranes. *American journal of obstetrics and gynecology*. 2015  
489 Feb;212(2):212.e1-9.
- 490 26. Kacerovsky M, Cobo T, Andrys C, Musilova I, Drahosova M, Hornychova H,  
491 et al. The fetal inflammatory response in subgroups of women with preterm prelabor  
492 rupture of the membranes. *The journal of maternal-fetal & neonatal medicine : the*  
493 *official journal of the European Association of Perinatal Medicine, the Federation of*  
494 *Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstet*.  
495 2013 May;26(8):795-801.
- 496 27. Leviton A, Hecht JL, Allred EN, Yamamoto H, Fichorova RN, Dammann O.  
497 Persistence after birth of systemic inflammation associated with umbilical cord  
498 inflammation. *Journal of reproductive immunology*. 2011 Aug;90(2):235-43.
- 499 28. Dammann O, Allred EN, Fichorova RN, Kuban K, O'Shea TM, Leviton A.  
500 Duration of Systemic Inflammation in the First Postnatal Month Among Infants Born  
501 Before the 28th Week of Gestation. *Inflammation*. 2016 Apr;39(2):672-7.

- 502 29. Leviton A, Allred EN, Yamamoto H, Fichorova RN, Kuban K, O'Shea TM, et  
503 al. Antecedents and correlates of blood concentrations of neurotrophic growth  
504 factors in very preterm newborns. *Cytokine*. 2017 Jun;94:21-8.
- 505 30. Boardman JP, Hall J, Thrippleton MJ, Reynolds RM, Bogaert D, Davidson DJ,  
506 et al. Impact of preterm birth on brain development and long-term outcome: protocol  
507 for a cohort study in Scotland. *BMJ Open*. 2020;10(3):e035854.
- 508 31. Redline RW, Faye-Petersen O, Heller D, Qureshi F, Savell V, Vogler C.  
509 Amniotic infection syndrome: nosology and reproducibility of placental reaction  
510 patterns. *Pediatric and developmental pathology : the official journal of the Society  
511 for Pediatric Pathology and the Paediatric Pathology Society*. 2003 Sep-  
512 Oct;6(5):435-48.
- 513 32. Liston A, Carr EJ, Linterman MA. Shaping Variation in the Human Immune  
514 System. *Trends in immunology*. 2016 Oct;37(10):637-46.
- 515 33. Motomura K, Romero R, Galaz J, Tarca AL, Done B, Xu Y, et al. RNA  
516 Sequencing Reveals Distinct Immune Responses in the Chorioamniotic Membranes  
517 of Women with Preterm Labor and Microbial or Sterile Intra-amniotic Inflammation.  
518 *Infection and Immunity*. 2021;89(5):e00819-20.
- 519 34. Rao R, Mashburn CB, Mao J, Wadhwa N, Smith GM, Desai NS. Brain-derived  
520 neurotrophic factor in infants <32 weeks gestational age: correlation with antenatal  
521 factors and postnatal outcomes. *Pediatric research*. 2009 May;65(5):548-52.
- 522 35. Huang EJ, Reichardt LF. Neurotrophins: roles in neuronal development and  
523 function. *Annu Rev Neurosci*. 2001;24:677-736.
- 524 36. Matoba N, Ouyang F, Mestan KK, Porta NF, Pearson CM, Ortiz KM, et al.  
525 Cord blood immune biomarkers in small for gestational age births. *Journal of  
526 developmental origins of health and disease*. 2011 Apr;2(2):89-98.
- 527 37. D'Angelo A, Ceccanti M, Petrella C, Greco A, Tirassa P, Rosso P, et al. Role  
528 of neurotrophins in pregnancy, delivery and postpartum. *European journal of  
529 obstetrics, gynecology, and reproductive biology*. 2020 Apr;247:32-41.
- 530 38. Flöck A, Weber SK, Ferrari N, Fietz C, Graf C, Fimmers R, et al. Determinants  
531 of brain-derived neurotrophic factor (BDNF) in umbilical cord and maternal serum.  
532 *Psychoneuroendocrinology*. 2016 Jan;63:191-7.
- 533 39. Skogstrand K, Hagen CM, Borbye-Lorenzen N, Christiansen M, Bybjerg-  
534 Grauholm J, Baekvad-Hansen M, et al. Reduced neonatal brain-derived neurotrophic  
535 factor is associated with autism spectrum disorders. *Translational psychiatry*. 2019  
536 Oct 7;9(1):252.
- 537 40. Kuban KCK, Heeren T, O'Shea TM, Joseph RM, Fichorova RN, Douglass L,  
538 et al. Among Children Born Extremely Preterm a Higher Level of Circulating  
539 Neurotrophins Is Associated with Lower Risk of Cognitive Impairment at School Age.  
540 *The Journal of pediatrics*. 2018 Oct;201:40-8.e4.
- 541 41. Leviton A, Joseph RM, Fichorova RN, Allred EN, Gerry Taylor H, Michael  
542 O'Shea T, et al. Executive Dysfunction Early Postnatal Biomarkers among Children  
543 Born Extremely Preterm. *Journal of neuroimmune pharmacology : the official journal  
544 of the Society on NeuroImmune Pharmacology*. 2019 Jun;14(2):188-99.
- 545 42. Merle NS, Noe R, Halbwachs-Mecarelli L, Fremeaux-Bacchi V, Roumenina  
546 LT. Complement System Part II: Role in Immunity. *Frontiers in immunology*. 2015  
547 2015-May-26;6(257).
- 548 43. Merle NS, Church SE, Fremeaux-Bacchi V, Roumenina LT. Complement  
549 System Part I – Molecular Mechanisms of Activation and Regulation. *Frontiers in  
550 immunology*. 2015 2015-June-02;6(262).

- 551 44. Schafer DP, Lehrman EK, Kautzman AG, Koyama R, Mardinly AR, Yamasaki  
552 R, et al. Microglia sculpt postnatal neural circuits in an activity and complement-  
553 dependent manner. *Neuron*. 2012 May 24;74(4):691-705.
- 554 45. Gorelik A, Sapir T, Ben-Reuven L, Reiner O. Complement C3 Affects Rac1  
555 Activity in the Developing Brain. *Front Mol Neurosci*; 2018. p. 150.
- 556 46. McGreal EP, Hearne K, Spiller OB. Off to a slow start: under-development of  
557 the complement system in term newborns is more substantial following premature  
558 birth. *Immunobiology*. 2012 Feb;217(2):176-86.
- 559 47. Grumach AS, Ceccon ME, Rutz R, Fertig A, Kirschfink M. Complement profile  
560 in neonates of different gestational ages. *Scandinavian journal of immunology*. 2014  
561 Apr;79(4):276-81.
- 562 48. Fragopoulou AF, Qian Y, Heijtz RD, Forssberg H. Can Neonatal Systemic  
563 Inflammation and Hypoxia Yield a Cerebral Palsy-Like Phenotype in Periadolescent  
564 Mice? *Molecular neurobiology*. 2019 2019/10/01;56(10):6883-900.
- 565 49. Magdalon J, Mansur F, Teles e Silva AL, de Goes VA, Reiner O, Sertié AL.  
566 Complement System in Brain Architecture and Neurodevelopmental Disorders.  
567 *Frontiers in neuroscience*. 2020 2020-February-05;14(23).
- 568 50. Werneburg S, Jung J, Kunjamma RB, Ha SK, Luciano NJ, Willis CM, et al.  
569 Targeted Complement Inhibition at Synapses Prevents Microglial Synaptic  
570 Engulfment and Synapse Loss in Demyelinating Disease. *Immunity*. 2020 Jan  
571 14;52(1):167-82.e7.
- 572 51. Alawieh A, Langley EF, Weber S, Adkins D, Tomlinson S. Identifying the Role  
573 of Complement in Triggering Neuroinflammation after Traumatic Brain Injury. *The  
574 Journal of neuroscience : the official journal of the Society for Neuroscience*. 2018  
575 Mar 7;38(10):2519-32.
- 576 52. Wu T, Dejanovic B, Gandham VD, Gogineni A, Edmonds R, Schauer S, et al.  
577 Complement C3 Is Activated in Human AD Brain and Is Required for  
578 Neurodegeneration in Mouse Models of Amyloidosis and Tauopathy. *Cell reports*.  
579 2019 Aug 20;28(8):2111-23.e6.
- 580 53. Fingleton B. Matrix metalloproteinases as regulators of inflammatory  
581 processes. *Biochimica et Biophysica Acta (BBA) - Molecular Cell Research*. 2017  
582 2017/11/01;1864(11, Part A):2036-42.
- 583 54. Reinhard SM, Razak K, Ethell IM. A delicate balance: role of MMP-9 in brain  
584 development and pathophysiology of neurodevelopmental disorders. *Frontiers in  
585 cellular neuroscience*. 2015 2015-July-29;9(280).
- 586 55. Okamoto T, Takahashi S, Nakamura E, Nagaya K, Hayashi T, Shirai M, et al.  
587 Increased expression of matrix metalloproteinase-9 and hepatocyte growth factor in  
588 the cerebrospinal fluid of infants with posthemorrhagic hydrocephalus. *Early human  
589 development*. 2010 Apr;86(4):251-4.
- 590 56. Walsh BH, Boylan GB, Kenny LC, Dempsey EM, Murray DM, Neonatal Brain  
591 Research G. Targeted Biomarker Discovery in Hypoxic-Ischemic Encephalopathy;  
592 Correlation with Early Continuous EEG. *Pediatric research*. 2011  
593 2011/11/01;70(5):134-.
- 594 57. Bednarek N, Svedin P, Garnotel R, Favrais G, Loron G, Schwendiman L, et  
595 al. Increased MMP-9 and TIMP-1 in mouse neonatal brain and plasma and in human  
596 neonatal plasma after hypoxia-ischemia: a potential marker of neonatal  
597 encephalopathy. *Pediatric research*. 2012 2012/01/01;71(1):63-70.
- 598 58. Savard A, Brochu M-E, Chevin M, Guiraut C, Grbic D, Sébire G. Neuronal  
599 self-injury mediated by IL-1 $\beta$  and MMP-9 in a cerebral palsy model of severe

600 neonatal encephalopathy induced by immune activation plus hypoxia-ischemia.  
601 Journal of neuroinflammation. 2015 2015/05/30;12(1):111.  
602